TERT across 13 cancers
TERT is on the target list of 13 of the briefings. No drug aimed at it carries an FDA label naming any of them; a drug against it is approved somewhere in 13. In the reference cohorts of the 12 with a mutation landscape it is altered in at least 5% of patients in 6 and in under 2% in 5 (Glioblastoma, Lower-grade glioma, Testicular cancer, Thyroid cancer, Vulvar cancer) — a target there by expression, dependency or drug label, not by mutation.
| Disease | Label status | Furthest stage (Open Targets) | Distinct drugs | Cell-therapy trials | Altered in the reference cohort |
|---|---|---|---|---|---|
| Anal cancer | approved elsewhere | approved | 1 | — | 5.76% mut · 1.44% amp n=139 |
| Bladder cancer | approved elsewhere | approved | 1 | — | 0.98% mut · 9.56% amp · 0.25% del n=410 |
| Cervical cancer | approved elsewhere | approved | 1 | — | 1.37% mut · 6.48% amp · 0.34% del n=291 |
| Glioblastoma | approved elsewhere | approved | 1 | — | 1.28% mut · 0.7% amp · 0.87% del n=390 |
| Head and neck cancer | approved elsewhere | approved | 1 | — | 0.58% mut · 5.03% amp n=515 |
| Hepatocellular carcinoma | approved elsewhere | approved | 1 | — | 0.55% mut · 5.45% amp · 0.27% del n=366 |
| Lower-grade glioma | approved elsewhere | approved | 1 | — | 0.39% mut · 0.59% amp · 0.59% del n=514 |
| Melanoma | approved elsewhere | approved | 1 | — | 4.11% mut · 5.18% amp · 0.82% del n=438 |
| Neuroblastoma | approved elsewhere | approved | 1 | — | no landscape |
| Soft tissue sarcoma | approved elsewhere | approved | 1 | — | 1.57% mut · 4.74% amp · 0.79% del n=255 |
| Testicular cancer | approved elsewhere | approved | 1 | — | 0.0% mut · 1.34% del n=149 |
| Thyroid cancer | approved elsewhere | approved | 1 | — | 0.61% mut · 0.2% amp · 0.2% del n=489 |
| Vulvar cancer | approved elsewhere | approved | 1 | — | 0.0% mut n=15 |
"Approved here" means a drug Open Targets records as aimed at TERT carries an FDA label that names that disease, per the briefing's openFDA stage. "Approved elsewhere" means the drug is approved for some other indication. Stage is the furthest Open Targets clinical stage among drugs aimed at the gene, in any indication; the database is reported as it is, and it lags some approvals. Cell-therapy trials are counted on the antigen the briefing maps the gene to, from ClinicalTrials.gov. The last column is the disease's mutation landscape: non-silent mutation, high-level amplification and deep deletion as percentages of the reference cohort's patients, each over its own denominator; "not on panel" means the reference cohort could not have called the gene.